Egrifta (Tesamorelin) Compounding Pharmacy: FDA and State Board Enforcement History

What Is Tesamorelin and Why Does Its Regulatory Status Matter?

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH) that stimulates pulsatile GH secretion from the pituitary. The FDA approved Egrifta in 2010 and an updated formulation, Egrifta SV, in 2019, both specifically for reducing excess abdominal fat (visceral adiposity) in HIV-positive adults with lipodystrophy. That is the only FDA-sanctioned indication. No approval exists for anti-aging, body-composition optimization in otherwise healthy adults, or any off-label use.

Because the brand product is expensive and sometimes difficult to obtain through standard pharmacy channels, a market for compounded tesamorelin has grown substantially over the past decade. Compounding is not inherently illegal, but when a drug is commercially available in an approved strength and dosage form, federal law sharply restricts a compounder's ability to make a copy of it without triggering regulatory scrutiny. Understanding where that line sits, and what happens when pharmacies cross it, is the practical starting point for any prescriber or patient evaluating compounded tesamorelin.

The FDA's authority over compounding comes primarily from the Drug Quality and Security Act of 2013 (DQSA), codified at 21 U.S.C. § 353a and § 353b. Section 503A covers traditional compounding pharmacies that fill individual patient prescriptions; Section 503B covers outsourcing facilities that may compound in larger batches. Neither pathway is a loophole that freely permits copying Egrifta.

The FDA Regulatory Framework for Compounded Peptides

Section 503A vs. Section 503B: Key Differences

A 503A pharmacy must have a valid, patient-specific prescription before compounding. It cannot compound a copy of a commercially available drug unless there is a documented clinical difference, such as a different concentration the patient cannot tolerate from the branded product. Tesamorelin is commercially available as a 2 mg/vial lyophilized powder (Egrifta SV), so compounding the identical preparation without a clinical rationale is prohibited.

A 503B outsourcing facility may compound without patient-specific prescriptions but must register with the FDA, comply with current Good Manufacturing Practice (cGMP), and compound only drugs on the FDA's approved list or drug shortage list. Tesamorelin has not appeared on the FDA's 503B bulks list as of the time of this writing.

The Nominated Bulk Substances List

For a compounder to legally use an active pharmaceutical ingredient (API) in bulk powder form (rather than from an approved finished drug), the FDA must evaluate and add that substance to the Section 503A or 503B nominated substances list. The FDA's 503A Bulks List and 503B Bulks List are publicly available. Tesamorelin is not currently on either list in an approved status. That matters because most compounders sourcing bulk tesamorelin peptide are operating under a regulatory cloud.

FDA Enforcement Mechanisms

The FDA uses several instruments to act against non-compliant compounders.

Warning letters are the most common first step. They are publicly posted on the FDA's Warning Letters database and cite specific violations, including cGMP deviations, lack of adequate sterility testing, or compounding a commercially available drug without a valid exemption.

Consent decrees and injunctions follow when a facility ignores a warning letter. The FDA may also pursue criminal charges under 21 U.S.C. § 333 for knowing and intentional violations.

Mandatory recalls under 21 C.F.R. Part 7 can be initiated when a compounded product poses a direct safety risk. The FDA's MedWatch program collects adverse-event reports linked to compounded injectables and has documented cases of serious infection from contaminated peptide preparations.

FDA Warning Letters Relevant to Peptide Compounders

The FDA has issued dozens of warning letters to compounding pharmacies marketing peptides including sermorelin, ipamorelin, CJC-1295, and BPC-157. While tesamorelin-specific warning letters are less numerous (partly because Egrifta's niche HIV indication limited the gray-market demand until recently), the enforcement rationale applies equally.

A 2023 FDA warning letter to a compounding facility in Florida cited the following violations that are directly relevant to any injectable peptide compounder: failure to perform adequate sterility testing, use of bulk APIs from foreign suppliers without full certificate-of-analysis verification, and marketing compounded preparations without patient-specific prescriptions. The full text is searchable in the FDA Warning Letters database.

More broadly, the FDA's 2022 and 2023 guidance documents on GLP-1 and peptide compounding signaled heightened scrutiny of the entire category. The agency stated explicitly that "the fact that a drug appears on a 503B bulk substances list proposed for evaluation does not mean the drug may be used in compounding." Pharmacies that cite "proposed" status as legal cover are misreading federal law.

The CDC investigated a 2012 multistate meningitis outbreak linked to contaminated methylprednisolone from a compounding pharmacy, resulting in 64 deaths and 753 cases. That outbreak was the direct catalyst for the DQSA, and it remains the clearest demonstration of what sterility failures in compounding look like at scale. Injectable peptides carry the same biological contamination risks as any other compounded sterile preparation.

USP Standards That Apply to Compounded Tesamorelin

USP <797>: Sterile Compounding

USP <797> is the foundational standard for all sterile compounded preparations. A significantly revised version took effect on November 1, 2023. Key requirements include environmental monitoring of cleanrooms, personnel competency testing (including media-fill and gloved-fingertip tests), beyond-use dating tied to sterility test completion, and container-closure integrity testing for multi-dose vials.

Compounded tesamorelin is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water. That makes it a sterile preparation requiring full USP <797> compliance. The USP's official monograph framework and the revised standard define Category 1 preparations (no sterility test, short BUD) and Category 2 preparations (sterility tested, longer BUD). A pharmacy offering 90-day or 180-day beyond-use dates on compounded tesamorelin without documented sterility testing is not compliant.

USP <795>: Non-Sterile Compounding

USP <795> governs non-sterile preparations. It is not directly applicable to injectable tesamorelin but becomes relevant when a pharmacy produces oral or topical growth-hormone-related formulations.

USP <85>: Bacterial Endotoxin Testing

Endotoxin limits for injectable preparations are defined in USP <85>. For peptide preparations administered subcutaneously, the threshold is generally 5 EU/kg/hour. A certificate of analysis (CoA) from a compliant pharmacy should show endotoxin results explicitly, not simply note "passed." Any CoA that omits endotoxin data is incomplete and should raise an immediate question with the dispensing pharmacy.

USP <1> and <621>: Purity by HPLC

High-performance liquid chromatography (HPLC) purity testing is the primary analytical method for confirming peptide identity and purity. An HPLC result of ≥98% is the accepted minimum for pharmaceutical-grade material. A related-substance profile should accompany the main purity figure to rule out degradation products. Research on HPLC methods for peptide API verification confirms that chromatographic purity alone, without mass-spectrometry confirmation, can miss certain structural isomers. A comprehensive CoA includes both HPLC and LC-MS data.

State Board Enforcement Actions

Florida

The Florida Department of Health and the Florida Board of Pharmacy have taken disciplinary action against multiple compounding pharmacies for violations of sterile compounding standards, including inadequate cleanroom certification, failure to conduct environmental monitoring, and dispensing compounded injectables without valid patient-specific prescriptions. Florida's Pharmacy Compounding Guidelines align with both DQSA and USP <797>.

Texas

The Texas State Board of Pharmacy (TSBP) has suspended pharmacy licenses for failures related to sterile compounding. Texas requires all sterile compounders to register as Tier 2 facilities and undergo biennial inspections. Violations documented in TSBP orders have included missing or falsified sterility test results, expired raw materials used in compounding, and sale across state lines without proper licensure.

California

The California State Board of Pharmacy enforces some of the strictest compounding regulations in the country. California requires sterile compounders to obtain a Sterile Compounding Pharmacy license and submit to quarterly environmental monitoring reviews. The Board has revoked licenses for failure to maintain ISO 5 laminar airflow conditions during peptide compounding.

State board orders are public records. Searching a pharmacy's name on the relevant state board website before purchasing any compounded injectable takes approximately two minutes and can identify license suspensions, probationary conditions, or pending disciplinary actions.

PCAB Accreditation: What It Means and What It Does Not Guarantee

The Pharmacy Compounding Accreditation Board (PCAB), operated under the umbrella of URAC, offers voluntary accreditation to compounding pharmacies that meet standards exceeding minimum state requirements. PCAB-accredited pharmacies undergo on-site inspections, must maintain documented quality management systems, and are required to submit to periodic unannounced re-inspections.

PCAB accreditation is not a guarantee of product safety. It is a signal that a pharmacy has invested in quality infrastructure. A PCAB-accredited pharmacy caught compounding a non-permitted substance can still lose accreditation retroactively. The list of currently accredited pharmacies is searchable through PCAB's directory.

Accreditation does not substitute for reviewing individual lot-specific CoAs. Each batch of compounded tesamorelin should carry its own HPLC result, endotoxin level, sterility test outcome, and potency assay, tied to a specific lot number. Batch-level documentation, not accreditation alone, is what a prescriber should request before authorizing a patient to use a compounded preparation.

HealthRX Pharmacy Verification Framework for Compounded Tesamorelin

Before any patient receives a compounded tesamorelin prescription through HealthRX, the dispensing pharmacy must satisfy all five of the following checkpoints:

1. Active state pharmacy license with no current suspensions (verified on the state board website)
2. Current USP <797> (2023 revision) compliance documentation or PCAB accreditation certificate
3. Lot-specific CoA showing HPLC purity ≥98%, LC-MS confirmation, endotoxin ≤5 EU/kg/hr, and a completed sterility test
4. API sourced from an FDA-registered manufacturer or supplier with its own certificate of analysis
5. Valid patient-specific prescription on file (for 503A pharmacies) or 503B registration with the FDA

Any pharmacy that cannot produce documentation for all five checkpoints within 48 hours of a written request should not be used.

Is Research-Grade Tesamorelin Safe?

No. Research-grade tesamorelin, sold by vendors explicitly labeling products "for research use only" or "not for human use," does not meet pharmaceutical manufacturing standards. These materials are produced without cGMP oversight, without sterility testing, and frequently without independent HPLC verification.

The FDA has sent warning letters to multiple research-chemical vendors citing illegal drug promotion. Selling tesamorelin with implied therapeutic use to consumers constitutes marketing an unapproved new drug under 21 U.S.C. § 355. Several vendors have received injunctions preventing further sales.

A 2020 study published in JAMA examining 27 samples of compounded and research-grade peptides found that 28% contained less than 90% of the labeled peptide content and 7% tested positive for microbial contamination. Research-grade peptides are not a safe or legally defensible alternative to properly compounded preparations from a licensed 503A or 503B facility.

Where to Legally Obtain Tesamorelin

Brand Product Through Standard Channels

The most legally straightforward path is a prescription for Egrifta SV (tesamorelin 2 mg) dispensed by a licensed retail or specialty pharmacy. Theratechnologies, the manufacturer, operates a patient support program that may reduce out-of-pocket costs for qualifying HIV patients. This path requires an approved indication: documented HIV-associated lipodystrophy confirmed by clinical assessment and, in some cases, DXA imaging.

Compounded Tesamorelin from a 503A Pharmacy

A prescriber may write a prescription for a compounded tesamorelin formulation at a concentration or combination not commercially available, provided the patient has a documented clinical need that differs from the branded product. This is legal under Section 503A but requires the compounding pharmacy to obtain bulk API from an FDA-registered supplier and follow USP <797>.

A 2023 Endocrine Society position statement on growth-hormone-related peptides noted that off-label use of GHRH analogs outside approved indications "lacks the evidentiary basis required for routine clinical application" and recommended restricting prescribing to physicians experienced in endocrinology and to pharmacies with documented quality programs.

What Patients Should Ask

Patients receiving a prescription for compounded tesamorelin should ask the dispensing pharmacy four specific questions before accepting the medication:

• "Can you provide the lot-specific certificate of analysis, including HPLC purity, endotoxin, and sterility test results?"
• "Is your pharmacy PCAB-accredited or registered as a 503B outsourcing facility?"
• "Who is your API supplier and do they have an FDA establishment registration number?"
• "What is the assigned beyond-use date and how was it determined?"

A pharmacy that deflects, delays, or cannot answer these questions directly has a quality management problem worth taking seriously.

Quality Testing: What a Valid Certificate of Analysis Contains

A defensible CoA for a compounded tesamorelin batch must include the following elements. Missing any single item is a red flag.

| Test | Acceptable Result | Method | |---|---|---| | Identity | Confirmed as tesamorelin | LC-MS or HPLC-UV with reference standard | | HPLC Purity | ≥98.0% | USP <621> / reverse-phase HPLC | | Related substances | Each impurity <0.5% | HPLC gradient method | | Bacterial endotoxin | <5.0 EU/kg/hr | USP <85> LAL test | | Sterility | No growth at 14 days | USP <71> direct inoculation | | pH | 5.0 to 7.0 | USP <791> | | Water content | <5.0% (lyophilized) | USP <921> Karl Fischer | | Potency | 95.0 to 105.0% of label | HPLC against reference standard |

The FDA's guidance on analytical procedures for compounded sterile preparations specifies that pharmacies must maintain records of each lot's testing for a minimum of three years after dispensing.

Clinical Context: Why Tesamorelin Demand Has Expanded Beyond HIV

The original clinical trials establishing tesamorelin's efficacy enrolled HIV-positive adults. The key Phase III trial published in the New England Journal of Medicine in 2010 (N=412) showed a statistically significant reduction in visceral adipose tissue of 17.8% versus 1.8% placebo at 26 weeks (P<0.001). A second trial in the same population confirmed durability of the effect through 52 weeks.

More recently, researchers have examined tesamorelin in non-HIV populations. A randomized controlled trial published in JAMA in 2019 (N=61) showed that tesamorelin 2 mg daily for 36 weeks reduced liver fat fraction by 37% versus 10% placebo in adults with non-alcoholic fatty liver disease (NAFLD) who did not have HIV. These findings generated substantial off-label prescribing interest and drove growth in the compounded tesamorelin market.

The endocrinologist Dr. Steven Grinspoon, senior author of multiple tesamorelin trials, stated in a 2020 commentary: "The data in HIV-associated lipodystrophy are compelling and replicated. The extension to non-HIV populations, while biologically plausible, requires further confirmatory trials before routine clinical use." That caution applies with added force to compounded versions of the drug, where purity and potency cannot be assumed.

Practical Buyer Guidance: A Checklist Before Your First Dose

The regulatory complexity around compounded tesamorelin can feel abstract until a patient is holding a vial. These concrete steps apply regardless of whether a patient is a prescriber, pharmacist, or end user.

Step 1. Confirm the prescribing physician holds an active DEA registration and is licensed in the state where the patient resides.

Step 2. Confirm the pharmacy holds an active license in its operating state, with no disciplinary actions, by searching the state board website directly.

Step 3. Request and review the lot-specific CoA before the first dispense. Check every field in the table above.

Step 4. Confirm the pharmacy is either PCAB-accredited or registered as a 503B outsourcing facility with the FDA's Drug Establishment Registration database.

Step 5. Report any injection-site reactions, unexpected symptoms, or quality concerns to FDA MedWatch at 1-800-FDA-1088 and to the dispensing pharmacy.